JPWO2019103998A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019103998A5
JPWO2019103998A5 JP2020545063A JP2020545063A JPWO2019103998A5 JP WO2019103998 A5 JPWO2019103998 A5 JP WO2019103998A5 JP 2020545063 A JP2020545063 A JP 2020545063A JP 2020545063 A JP2020545063 A JP 2020545063A JP WO2019103998 A5 JPWO2019103998 A5 JP WO2019103998A5
Authority
JP
Japan
Prior art keywords
composition
nanobiological
patient
spleen
nanoscale assembly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020545063A
Other languages
English (en)
Japanese (ja)
Other versions
JP7330994B2 (ja
JP2021504446A5 (https=
JP2021504446A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/061935 external-priority patent/WO2019103998A2/en
Publication of JP2021504446A publication Critical patent/JP2021504446A/ja
Publication of JP2021504446A5 publication Critical patent/JP2021504446A5/ja
Publication of JPWO2019103998A5 publication Critical patent/JPWO2019103998A5/ja
Priority to JP2023130072A priority Critical patent/JP7772748B2/ja
Application granted granted Critical
Publication of JP7330994B2 publication Critical patent/JP7330994B2/ja
Priority to JP2025187368A priority patent/JP2026015394A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020545063A 2017-11-21 2018-11-20 治療用ナノ生物学的組成物による訓練免疫の促進 Active JP7330994B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023130072A JP7772748B2 (ja) 2017-11-21 2023-08-09 治療用ナノ生物学的組成物による訓練免疫の促進
JP2025187368A JP2026015394A (ja) 2017-11-21 2025-11-06 治療用ナノ生物学的組成物による訓練免疫の促進

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589054P 2017-11-21 2017-11-21
US62/589,054 2017-11-21
PCT/US2018/061935 WO2019103998A2 (en) 2017-11-21 2018-11-20 Promoting trained immunity with therapeutic nanobiologic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023130072A Division JP7772748B2 (ja) 2017-11-21 2023-08-09 治療用ナノ生物学的組成物による訓練免疫の促進

Publications (4)

Publication Number Publication Date
JP2021504446A JP2021504446A (ja) 2021-02-15
JP2021504446A5 JP2021504446A5 (https=) 2023-05-23
JPWO2019103998A5 true JPWO2019103998A5 (https=) 2023-05-23
JP7330994B2 JP7330994B2 (ja) 2023-08-22

Family

ID=66630773

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020545063A Active JP7330994B2 (ja) 2017-11-21 2018-11-20 治療用ナノ生物学的組成物による訓練免疫の促進
JP2023130072A Active JP7772748B2 (ja) 2017-11-21 2023-08-09 治療用ナノ生物学的組成物による訓練免疫の促進
JP2025187368A Pending JP2026015394A (ja) 2017-11-21 2025-11-06 治療用ナノ生物学的組成物による訓練免疫の促進

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023130072A Active JP7772748B2 (ja) 2017-11-21 2023-08-09 治療用ナノ生物学的組成物による訓練免疫の促進
JP2025187368A Pending JP2026015394A (ja) 2017-11-21 2025-11-06 治療用ナノ生物学的組成物による訓練免疫の促進

Country Status (7)

Country Link
US (4) US20200261591A1 (https=)
EP (1) EP3713548A4 (https=)
JP (3) JP7330994B2 (https=)
CN (1) CN111971028A (https=)
AU (2) AU2018370828B2 (https=)
CA (1) CA3082830A1 (https=)
WO (1) WO2019103998A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4014967A1 (en) 2016-04-29 2022-06-22 Icahn School of Medicine at Mount Sinai Targeting the innate immunesystem to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
US20230266321A1 (en) * 2020-06-25 2023-08-24 Icahn School Of Medicine At Mount Sinai Live cell engagement assay
CN118459539B (zh) * 2021-03-19 2026-01-06 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore
CA3222851A1 (en) 2021-06-22 2022-12-29 Roy VAN DER MEEL Nucleic acid containing nanoparticles
WO2023192956A2 (en) * 2022-03-31 2023-10-05 Icahn School Of Medicine At Mount Sinai Sphingolipid-loaded nanobiologics for immune regulation
JP2025518282A (ja) 2022-06-03 2025-06-12 バイオ－トリップ ベーフェー 核酸送達のための多価分子に基づく脂質ナノ粒子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101096386A (zh) * 2007-06-05 2008-01-02 复旦大学 Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用
CN101903018B (zh) * 2007-10-17 2012-09-05 韩国科学技术院 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法
CN105903029A (zh) * 2007-12-12 2016-08-31 大学健康网络 高密度脂蛋白样肽磷脂支架（“hpps”）纳米颗粒
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2012026712A2 (ko) * 2010-08-23 2012-03-01 주식회사 강스템홀딩스 Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
KR20160093012A (ko) * 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
WO2016154544A1 (en) * 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
CN106714836A (zh) * 2015-06-05 2017-05-24 H·李·莫菲特癌症中心研究有限公司 Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗
WO2017024312A1 (en) * 2015-08-06 2017-02-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods

Similar Documents

Publication Publication Date Title
Chen et al. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer
Dash et al. Targeted radionuclide therapy-an overview
JP4868698B2 (ja) マクロファージが仲介する疾患の治療および診断
Kitson et al. Radionuclide antibody-conjugates, a targeted therapy towards cancer
US20100178245A1 (en) Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
JP7084350B2 (ja) 放射線療法用粒子と懸濁液
RS66467B1 (sr) Kompleks koji se sastoji iz jedinjenja koje cilja psma vezano sa radionuklidom olova ili torijuma
RU2741794C2 (ru) Радиофармацевтические растворы с предпочтительными свойствами
Zhao et al. Targeted radionuclide therapy in glioblastoma
Qin et al. Effective treatment of SSTR2-positive small cell lung cancer using 211At-containing targeted α-particle therapy agent which promotes endogenous antitumor immune response
DE19845798A1 (de) Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
JP7128528B2 (ja) 標的投与のための放射性標識物質
US9242016B2 (en) Gold coated lanthanide nanoparticles
CA3031776A1 (en) Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
JPWO2019103998A5 (https=)
Wu et al. Expanding horizons in theragnostics: from oncology to multidisciplinary applications
US20100178244A1 (en) Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
Petrosova et al. Preclinical evaluation of 68Ga-labeled folic acid conjugates for visualization of inflammatory foci
Dormehl et al. Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model
Farzipour et al. Evaluation of the Effect of Chelating Arms and Carrier Agents on the Radiotoxicity of TAT Agents
US20250135049A1 (en) Methods for Biological Material Labeling and Medical Imaging
TW201726179A (zh) 純化方法
JP2011518197A (ja) マクロ分子を放射性標識化するための方法
Yuv et al. Experimental study of dendrimer-based nanoparticles with RGD-peptide for anticancer radionuclide therapy
Nemtsova et al. Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer